Timentin in the treatment of invasive burn wound infection with sepsis.
Twenty-one patients with infected burns were treated with 5.2 g Timentin (ticarcillin 5 g + potassium clavulanate 200 mg) three times a day for an average of 8.3 days. Staphylococcus aureus was the commonest pathogen, there being ten cases of septicaemia with this organism and all were cured. Three patients with Pseudomonas aeruginosa septicaemia and infections with methicillin-resistant S. aureus failed. No drug related side effects were noted.
D000328:Adult; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002056:Burns / Q000150:complications*; D002969:Clavulanic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D013982:Ticarcillin / Q000494:pharmacology / Q000627:therapeutic use*
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin